Cingulate Inc.

NasdaqCM CING

Cingulate Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024

Cingulate Inc. Shares (Diluted, Weighted) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Cingulate Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 56,333, a 28.28% change year over year.
Cingulate Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 43,914, a -6.81% change year over year.
Cingulate Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 47,122.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: CING

Cingulate Inc.

CEO	Dr. Shane J. Schaffer Pharm.D.
IPO Date	Dec. 8, 2021
Location	United States
Headquarters	1901 West 47th Place
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Key trends

Past 5 years